Nasdaq · Biotech stocks database

IPHA — Innate Pharma S.A.

IPHA (Innate Pharma S.A.) stock: $1.90, $212.2M market cap, $33.0M cash, $179.2M EV, $186.7M fully diluted market cap. Next expected readout: Jun-27. Lead program: IPH5201 (Non Small Cell Lung Cancer), Phase 2. Data from Fully Diluted's biotech stocks database.

Share price

$1.90

Market cap

$212.2M

Cash

$33.0M

Enterprise value

$179.2M

Balance sheet

Cash	$33.0M
Debt	$0.0M
Net cash	$33.0M
Enterprise value	$179.2M
Basic shares	93.7M shares
Fully diluted shares	98.3M shares
Fully diluted market cap	$186.7M
Cash per share	$0.35

Cash figures as of 2025-12-31. Database snapshot: 2026-09-21.

Price history

Loading IPHA daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jul 13 - Aug 24	IPH5201	Phase 2	Non Small Cell Lung Cancer	—
May 13 - Jun 24	IPH4502	Phase 1	Advanced or Metastatic Solid Tumors	—
Jun 11 - Jul 23	Lacutamab	Phase 2	Peripheral T Cell Lymphoma; Relapse/Recurrence	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Lead drug	IPH5201
Lead indication	Non Small Cell Lung Cancer
Lead phase	Phase 2
Active trials	2
Collaborator trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05742607	Phase 2	Recruiting	Sponsor	Innate Pharma	—	Non Small Cell Lung Cancer	—
NCT06781983	Phase 1	Active, not recruiting	Sponsor	Innate Pharma	—	Advanced or Metastatic Solid Tumors	—
NCT04590963	Phase 3	Active, not recruiting	Collaborator	AZN	AZN	Squamous Cell Carcinoma of the Head and Neck	—
NCT04984837	Phase 2	Active, not recruiting	Collaborator	The Lymphoma Academic Research Organisation	—	Peripheral T Cell Lymphoma; Relapse/Recurrence	—
NCT05143970	Phase 1	Active, not recruiting	Collaborator	Institut Paoli-Calmettes	—	Metastatic Cancer; Metastatic Breast Cancer; Metastatic Pancreatic Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 3 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Innate Pharma on ClinicalTrials.gov

Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 714 stocks.

Subscribe to Compounding Ego

IPHA — Innate Pharma S.A.

Balance sheet

Price history

Upcoming catalysts

Pipeline

Active clinical trials